AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31043129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with partial blood flow restriction (LL-BFR, e.g. 20% 1RM)
Number of subjects: 10
Study 31892724 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in chopstick use with the non-dominant (left) hand for 6 weeks
Number of subjects: 32
Study 31892724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study 28238522 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus endovascular treatment
Number of subjects: 77
Study 28238522 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study 24807875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 68
Study 23622053 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6D
Number of subjects: 172
Study 23622053 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ5D
Number of subjects: 172
Study 23622053 — intervention group
Group type: EXPERIMENTAL
Intervention: ODI
Number of subjects: 172
Study 21813857 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV vaccine (34 subjects; four received 1/10th dose)
Number of subjects: 51
Study 21813857 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (17 subjects; dose 1: live varicella; dose 2: Haemophilus influenzae type b)
Number of subjects: 51
Study 19356272 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-energy orangeade with large sips (20 g/sip)
Number of subjects: 53
Study 19356272 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-energy orangeade with small sips (5 g/sip)
Number of subjects: 53
Study 19356272 — intervention group
Group type: EXPERIMENTAL
Intervention: No-energy orangeade with large sips (20 g/sip)
Number of subjects: 53
Study 19356272 — intervention group
Group type: EXPERIMENTAL
Intervention: No-energy orangeade with small sips (5 g/sip)
Number of subjects: 53
Study 16422734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support algorithm
Number of subjects: 42
Study 16422734 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding practices (control)
Number of subjects: 42
Study 15541408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal sterilization (TS)
Number of subjects: 36
Study 15541408 — intervention group
Group type: COMPARATOR
Intervention: Control group (barrier method)
Number of subjects: 36
Study 11930720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mm excessive crown contour
Number of subjects: 12
Study 11930720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mm excessive crown contour
Number of subjects: 12
Study 11930720 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mm excessive crown contour
Number of subjects: 12
Study 8995749 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)‐vitamin D2, 4 micrograms/day or 4 micrograms thrice weekly, adjusted over 12 weeks
Number of subjects: 24
Study 8995749 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)‐vitamin D2
Number of subjects: 24
Study 8431571 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study 8431571 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls
Number of subjects: 30
Study 8431571 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-propylene glycol (APG)
Number of subjects: 30
Study 3680575 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated KCl capsule preparation
Number of subjects: 16
Study 3680575 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax-matrix formulation
Number of subjects: 16
Study 3680575 — intervention group
Group type: EXPERIMENTAL
Intervention: New microencapsulated KCl tablet preparation
Number of subjects: 16
Study 3680575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3680575 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 16
Study 29343280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin plus evidence-based advice
Number of subjects: 30
Study 29343280 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus evidence-based advice
Number of subjects: 30
Study 27143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg weekly)
Number of subjects: 257
Study 27143690 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (standard chemo‐radiotherapy)
Number of subjects: 257
Study 27143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylation of mTORSer2448 in tumor tissue
Number of subjects: 257
Study 27004344 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed lateral internal anal sphincterotomy (CLIAS) via von‐greaves knife
Number of subjects: 94
Study 27004344 — intervention group
Group type: COMPARATOR
Intervention: Open internal anal sphincterotomy (OIAS) (Park's procedure)
Number of subjects: 94
Study 24078509 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Number of subjects: 43
Study 24078509 — intervention group
Group type: COMPARATOR
Intervention: No fibrin glue (Control)
Number of subjects: 43
Study 21360491 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (2 × 500 mg intravenously)
Number of subjects: 51
Study 21360491 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 51
Study 21360491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 18165599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 90 mg (9 mL), morphine 4 mg (10 mL), and ketorolac 30 mg (1 mL) (total volume 20 mL)
Number of subjects: 51
Study 18165599 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 mL)
Number of subjects: 51
Study 18165599 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac 30 mg (1 mL)
Number of subjects: 51
Study 18165599 — intervention group
Group type: COMPARATOR
Intervention: IV saline (1 mL)
Number of subjects: 51
Study 17126780 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 3501
Study 17126780 — intervention group
Group type: COMPARATOR
Intervention: No postoperative epidural analgesia (Control)
Number of subjects: 3501
Study 12948794 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocaine (10 mg/ml)
Number of subjects: 11
Study 12948794 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%)
Number of subjects: 11
Study 12948794 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw gape of 14 mm
Number of subjects: 11
Study 10970994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically interesterified butter
Number of subjects: 0
Study 10970994 — intervention group
Group type: COMPARATOR
Intervention: Native butter
Number of subjects: 0
Study 7521662 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) with high-dose melphalan, and additional treatments including fractionated total body irradiation, hemi-body irradiation, and high-dose etoposide.
Number of subjects: 30
Study 7521662 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 30
Study 2511684 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 2.5 mg isosorbide dinitrate (ISDN)
Number of subjects: 608
Study 2511684 — intervention group
Group type: COMPARATOR
Intervention: 5 x 40 mg isosorbide dinitrate (ISDN)
Number of subjects: 608
Study 2511684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ISDN
Number of subjects: 608
Study 2511684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ISDN
Number of subjects: 608
Study 128287 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella trivalent vaccine
Number of subjects: 1481
Study 128287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1481
Study 30901529 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 8 weeks
Number of subjects: 27
Study 28356484 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 92
Study 28356484 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 26520396 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg corifollitropin alfa
Number of subjects: 694
Study 24992752 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs
Number of subjects: 433
Study 24992752 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 433
Study 23011563 — intervention group
Group type: COMPARATOR
Intervention: Toy (group 2)
Number of subjects: 130
Study 23011563 — intervention group
Group type: COMPARATOR
Intervention: Animated cartoon (group 3)
Number of subjects: 130
Study 23011563 — intervention group
Group type: COMPARATOR
Intervention: Control (group 1)
Number of subjects: 130
Study 19606690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenterics Intragastric Balloon (BIB)
Number of subjects: 21
Study 19606690 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 21
Study 17882847 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported by a clinician and an information analyst in obtaining and analysing their own data
Number of subjects: 0
Study 17882847 — intervention group
Group type: COMPARATOR
Intervention: Unsupported
Number of subjects: 0
Study 14692015 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 40
Study 14692015 — intervention group
Group type: COMPARATOR
Intervention: Yoga Stretching (Hatha)
Number of subjects: 40
Study 12137238 — intervention group
Group type: EXPERIMENTAL
Intervention: El Paso CATCH
Number of subjects: 24
Study 9819584 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Error Identification techniques (specifically SHERPA)
Number of subjects: 0
Study 7568638 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated trials of the same erotic stimulus
Number of subjects: 62
Study 7568638 — intervention group
Group type: EXPERIMENTAL
Intervention: A series of varying erotic stimuli
Number of subjects: 62
Study 1663200 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 1663200 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study 7020890 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated lidocaine 1.73%
Number of subjects: 20
Study 7020890 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride 2.0%
Number of subjects: 20
Study 29899050 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme (60 min, 3 days per week throughout pregnancy)
Number of subjects: 124
Study 25807517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Cycling (SIT)
Number of subjects: 25
Study 23604689 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (4 mg annually)
Number of subjects: 43
Study 23604689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 21476064 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (2 mg single oral dose)
Number of subjects: 177
Study 19584487 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate with phototherapy
Number of subjects: 68
Study 17374042 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 103
Study 17374042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills Therapy (CBCST)
Number of subjects: 103
Study 17374042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 15338385 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary biking 30 min five times weekly)
Number of subjects: 72
Study 15338385 — intervention group
Group type: COMPARATOR
Intervention: Progressive relaxation training (45 min three times per week)
Number of subjects: 72
Study 11332146 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, 5‐fluorouracil (5‐FU), leucovorin, and interferon‐alpha 2b (PFL‐IFN) followed by concomitant chemoradiation with 5‐FU, hydroxyurea, and total radiotherapy dose of 7000 cGy (FHX)
Number of subjects: 32
Study 9554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent calcitriol (1,25D) therapy
Number of subjects: 16
Study 9554570 — intervention group
Group type: COMPARATOR
Intervention: Daily 1,25D therapy
Number of subjects: 16
Study 8017327 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate-HCl (20 mmol Mg/d)
Number of subjects: 91
Study 8017327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 2472596 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy (10-day trial)
Number of subjects: 196
Study 2472596 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy (3 months)
Number of subjects: 196
Study 2472596 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic infants
Number of subjects: 196
Study 2472596 — intervention group
Group type: COMPARATOR
Intervention: Control infants and nonanemic iron-deficient infants
Number of subjects: 196
Study 30875390 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg intravenously three times weekly (TIW) after hemodialysis, with potential dose increases of 2.5 or 5 mg at 4-week intervals to a maximum dose of 15 mg TIW.
Number of subjects: 3025
Study 30875390 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet (active control).
Number of subjects: 3025
Study 30875390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control).
Number of subjects: 3025
Study 28508114 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol mouthwash
Number of subjects: 8
Study 28508114 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 8
Study 25603851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate Tablets (SPT)
Number of subjects: 189
Study 25603851 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene Glycol with Ascorbic Acid (PEGA)
Number of subjects: 189
Study 23612519 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemedicine
Number of subjects: 44
Study 23612519 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital admission
Number of subjects: 44
Study 20458210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab alone (Arm A)
Number of subjects: 32
Study 20458210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus docetaxel (Arm B)
Number of subjects: 32
Study 20458210 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 32
Study 18302787 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised exercise and nutrition program (six months duration, commencing within 14 days post-surgery)
Number of subjects: 460
Study 18302787 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 460
Study 17151965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 50
Study 17151965 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 50
Study 14559383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 1006
Study 14559383 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 1006
Study 10710555 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (50 mU. kg(‐1). h(‐1))
Number of subjects: 8
Study 10710555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ANP infusion (0.3 pmol. kg(‐1). h(‐1))
Number of subjects: 8
Study 10710555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ANP infusion (2 microg/min)
Number of subjects: 8
Study 9181268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (100 mg daily for 12 weeks)
Number of subjects: 201
Study 9181268 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem CD (360 mg daily for 12 weeks)
Number of subjects: 201
Study 9181268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil or Diltiazem CD during withdrawal period
Number of subjects: 201
Study 9181268 — intervention group
Group type: COMPARATOR
Intervention: Placebo during withdrawal period
Number of subjects: 201
Study 8474278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (3 x 50 mg/day for 1 month, then 3 x 100 mg/day for 2 months)
Number of subjects: 90
Study 8474278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 4078054 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine-impregnated polyethylene oxide gel (PVPI-POG) dressing
Number of subjects: 45
Study 4078054 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene oxide gel (POG) dressing
Number of subjects: 45
Study 30153194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume group performing one set per exercise per training session (n = 11)
Number of subjects: 34
Study 30153194 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume group performing three sets per exercise per training session (n = 12)
Number of subjects: 34
Study 30153194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume group performing five sets per exercise per training session (n = 11)
Number of subjects: 34
Study 30153194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume group
Number of subjects: 34
Study 30153194 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume group
Number of subjects: 34
Study 30153194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume group
Number of subjects: 34
Study 29310444 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 5 mg
Number of subjects: 410
Study 29310444 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 50 mg
Number of subjects: 410
Study 29310444 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 410
Study 29310444 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg
Number of subjects: 410
Study 29310444 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 410
Study 29310444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 26933148 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Reserve (HRR) method
Number of subjects: 14
Study 26933148 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent of 220-age method
Number of subjects: 14
Study 26933148 — intervention group
Group type: COMPARATOR
Intervention: VO2peak
Number of subjects: 14
Study 25204768 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed, multicomponent exercise program
Number of subjects: 152
Study 22092973 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM + AB supplemented with autogenous bone cells
Number of subjects: 20
Study 22092973 — intervention group
Group type: COMPARATOR
Intervention: DBBM + AB alone
Number of subjects: 20
Study 19590158 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of thermal water (TW) for 2 weeks
Number of subjects: 13
Study 19590158 — intervention group
Group type: COMPARATOR
Intervention: Normal saline inhalation
Number of subjects: 13
Study 17403741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing sealant (Group 2)
Number of subjects: 45
Study 17403741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant with high fluoride release (Group 3)
Number of subjects: 45
Study 17403741 — intervention group
Group type: COMPARATOR
Intervention: Conventional sealant without fluoride (Group 1)
Number of subjects: 45
Study 16327030 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 6% w/v)
Number of subjects: 6
Study 16327030 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+VC
Number of subjects: 6
Study 16327030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC, 0.15% w/v)
Number of subjects: 6
Study 16327030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6
Study 11943036 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care (tooth brushing after each meal, swabbing with povidone iodine, professional care once a week)
Number of subjects: 417
Study 11943036 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care
Number of subjects: 417
Study 11943036 — intervention group
Group type: COMPARATOR
Intervention: No oral care
Number of subjects: 417
Study 9784543 — intervention group
Group type: EXPERIMENTAL
Intervention: C3b/c levels
Number of subjects: 52
Study 9784543 — intervention group
Group type: EXPERIMENTAL
Intervention: C3-CRP levels
Number of subjects: 52
Study 9784543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 52
Study 9784543 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement activation products
Number of subjects: 52
Study 7664863 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled platelet‐activating factor (PAF) 225 micrograms
Number of subjects: 8
Study 7664863 — intervention group
Group type: COMPARATOR
Intervention: Lyso‐PAF 225 micrograms
Number of subjects: 8
Study 7664863 — intervention group
Group type: COMPARATOR
Intervention: Saline bronchial challenge
Number of subjects: 8
Study 2673479 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 23
Study 2673479 — intervention group
Group type: COMPARATOR
Intervention: Relatives group (compliant families)
Number of subjects: 23
Study 2673479 — intervention group
Group type: COMPARATOR
Intervention: Relatives group (non-compliant families)
Number of subjects: 23
Study 2673479 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy and relatives group (general outcome)
Number of subjects: 23
Study 2673479 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in EE and/or contact
Number of subjects: 23
Study 30012798 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular telephone calls and home visits by healthcare professionals after discharge from hospital.
Number of subjects: 0
Study 27630497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive Glass (BAG)
Number of subjects: 22
Study 27630497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 22
Study 25432324 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK interbody cages containing calcium sulphate/demineralized bone matrix (CS/DBM)
Number of subjects: 68
Study 25432324 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac cancellous bone (AIB)
Number of subjects: 68